

Associated Autoimmune Diseases in Systemic Sclerosis Define a Subset of Patients with Milder Disease: Results from 2 Large Cohorts of European Caucasian Patients

JÉRÔME AVOUAC, PAOLO AIRÒ, PHILIPPE DIEUDE, PAOLA CARAMASCHI, KIET TIEV, ELISABETH DIOT, JEAN SIBILIA, SUSANNA CAPPELLI, BRIGITTE GRANEL, ALESSANDRA VACCA, JULIEN WIPFF, OLIVIER MEYER, ANDRÉ KAHAN, MARCO MATUCCI-CERINIC, and YANNICK ALLANORE

ABSTRACT. *Objective.* To assess the prevalence and potential associations with the systemic sclerosis (SSc) phenotype of additional autoimmune diseases (AID).

Methods. A multicenter study was performed in France and Italy to recruit consecutive European Caucasian patients with SSc systematically assessed for the coexistence of predefined AID known to occur with connective tissue diseases.

Results. We recruited 585 French and 547 Italian patients with SSc. Specific AID were found in 114/585 (19%) French and 179/547 (33%) Italians with SSc ($p < 0.0001$). Sjögren's syndrome and thyroiditis were the predominant AID in both cohorts (12% for Sjögren's syndrome and 6% for thyroiditis in the combined populations). The frequency of myositis, primary biliary cirrhosis, rheumatoid arthritis, and systemic lupus erythematosus was low ($< 4\%$) and similar in both cohorts. The coexistence of at least 1 of the AID in the whole cohort was associated in multivariate analysis with the limited cutaneous subtype, the presence of antinuclear antibodies, and a lower prevalence of digital ulcers.

Conclusion. Our study shows that 21% of this large series of European Caucasian patients with SSc have developed at least 1 AID. This latter condition identified a subset of patients with milder disease. Thus, associations of AID and autoimmune background in SSc have to be considered for further therapeutic and biological investigations in SSc. (First Release Feb 1 2010; *J Rheumatol* 2010;37:608–14; doi:10.3899/jrheum.090815)

Key Indexing Terms:

SYSTEMIC SCLEROSIS
SJÖGREN'S SYNDROME

AUTOIMMUNITY

THYROIDITIS
PRIMARY BILIARY CIRRHOSIS

Systemic sclerosis (SSc) is a severe connective tissue disorder characterized by alterations of the microvasculature, disturbances of the immune system, and the massive deposition of collagen in connective tissue¹. Although the mechanisms that underlie these changes are not entirely clear, it has been suggested that immunological abnormalities play a key role in the pathogenesis of the disease, supported by the detection of various autoantibodies in the serum of

patients with SSc. Autoantibody specificity may associate with disease phenotype, as anticentromere antibodies (ACA) are usually found in the limited cutaneous subtype and correlate positively with ischemic digital loss and development of pulmonary arterial hypertension. On the other hand, antitopoisomerase I antibodies are mainly detected in the diffuse cutaneous subtype, in association with fibrosing alveolitis and heart involvement^{2,3}.

From Rheumatology A Department, Paris Descartes University, Cochin Hospital; Rheumatology Department, Paris 7 University, Bichat Claude Bernard Hospital; Internal Medicine Department, Saint Antoine Hospital, APHP, Paris; INSERM EMI-U 00-10, CHU Bretonneau, Tours; Rheumatology Department, Louis Pasteur University, Haute-pierre Hospital, Strasbourg; Internal Medicine Department, North Hospital 19915, Marseille, France; Rheumatology and Clinical Immunology, Spedali Civili, Brescia; Department of Clinical and Experimental Medicine – Rheumatology Unit, University of Verona, Verona; Department of Biomedicine, Section of Rheumatology, University of Florence, Florence; and Rheumatology Department, University of Cagliari, Cagliari, Italy.

J. Avouac, MD, PhD; J. Wipff, MD, PhD; A. Kahan, MD, PhD; Y. Allanore, MD, PhD, Rheumatology A Department, Paris Descartes University, Cochin Hospital; P. Dieude, MD, PhD; O. Meyer, MD, PhD,

Rheumatology Department, Paris 7 University, Bichat Claude Bernard Hospital; K. Tiev, MD, Internal Medicine Department, Saint Antoine Hospital, APHP; E. Diot, MD, INSERM EMI-U 00-10, CHU Bretonneau; J. Sibilias, MD, PhD, Rheumatology Department, Louis Pasteur University, Haute-pierre Hospital; B. Granel, MD, Internal Medicine Department, North Hospital 19915; P. Airò, MD, Rheumatology and Clinical Immunology, Spedali Civili; P. Caramaschi, MD, Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Verona; S. Cappelli, MD; M. Matucci-Cerinic, MD, PhD, Department of Biomedicine, Section of Rheumatology, University of Florence; A. Vacca, MD, Second Chair of Rheumatology, University of Cagliari.

Address correspondence to Dr. J. Avouac, Hôpital Cochin, Service de Rhumatologie A, 27 Rue du Faubourg Saint Jacques, 75014 Paris, France. E-mail: javouac@yahoo.fr

Accepted for publication October 11, 2009.

Some evidence also supports a potential causal role in the pathogenesis of the disease for antitopoisomerase I and platelet derived growth factor receptor (PDGFR) autoantibodies. Antitopoisomerase I antibodies are highly specific for SSc, are present in high titers extremely early in the disease process, and correlate with disease activity/severity⁴. Stimulatory autoantibodies against PDGFR also appear to be a specific hallmark of SSc and display biologic activity on fibroblasts⁵.

Although scarce data are available, preliminary results suggest that SSc could be associated with other autoimmune diseases (AID)⁶. However, their precise frequency in a large cohort of patients and their effect on disease phenotype remain unclear. We previously assessed the prevalence of secondary Sjögren's syndrome (SS) in a prospective 2-center series of 133 patients with SSc⁷. SS was diagnosed in 14% of our patients and was much more common in the limited cutaneous form of SSc, and was associated with lower frequency of pulmonary fibrosis. However, in that study we did not evaluate overlap between SSc and other AID known to be associated with connective tissue diseases (CTD), such as autoimmune thyroiditis, myositis, primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), or systemic lupus erythematosus (SLE)⁶.

The aims of our study were to assess the prevalence of AID known to be associated with CTD in 2 large and consecutive populations of European Caucasian subjects with SSc from France and Italy, and to determine potential associations between the presence of AID and the phenotype of patients with SSc in the combined population.

MATERIALS AND METHODS

A multicenter study was performed in France and Italy to recruit consecutive European Caucasian patients with SSc. A first set of successive French patients with SSc from 6 centers was included to design a primary cohort. A second set of consecutive Caucasian Italian patients with SSc from 5 centers was included to form a secondary cohort.

We carried out a complete evaluation of these patients based on the following data: age, sex, cutaneous SSc subtype as defined by LeRoy, *et al*⁸, disease duration (date of first non-Raynaud symptom), duration of Raynaud's phenomenon, and digital ulceration. Systemic assessment was carried out as recommended⁹. We used computed tomography and respiratory function tests [forced vital capacity (FVC) and carbon monoxide diffusion capacity divided by alveolar volume (DLCO/AV)] to assess pulmonary fibrosis. An echocardiographically estimated systolic pulmonary arterial pressure (PAP) > 40 mm Hg was used as a screening threshold for suspicion of pulmonary arterial hypertension (PAH). Patients identified by this preliminary screening were offered right-heart catheterization. Confirmed PAH was defined as a resting mean PAP \geq 25 mm Hg with a pulmonary capillary wedge pressure of \leq 15 mm Hg, measured by right-heart catheterization¹⁰. The following biological tests were carried out: routine blood tests, serological testing for antinuclear antibodies (ANA) or ACA (immunofluorescence on HEP-2 cells), and antitopoisomerase I/anti-U1 ribonucleoprotein antibodies (counter immunoelectrophoresis and/or immunodiffusion).

Patients with SSc were systematically assessed for the coexistence of AID known to be associated with CTD in order to compare their respective frequencies among these 2 groups. Then the 2 cohorts were combined to build a large series of patients allowing determination of the disease phe-

notype influence of AID. These latter were defined in accord with standard international criteria (Table 1). SS was defined by the revised American-European consensus classification criteria for SS¹¹; SLE and RA were defined by the revised classification criteria from the American College of Rheumatology^{12,13}. Autoimmune thyroiditis¹⁴, PBC¹⁵, and myositis^{16,17} were diagnosed as reported following clinical, biological, and histological criteria (Table 2).

All patients gave informed consent for all procedures, which were carried out with local ethics committee approval. The study was conducted in accord with the recommendations of the Helsinki Declaration and all investigations were those routinely required to evaluate the patients.

Statistical analysis. All data are presented as mean (standard deviation, SD) for continuous variables and numbers and percentages for categorical variables, unless stated otherwise. Data were statistically analyzed using chi-squared tests for differences in frequency and parametric Student's t-test for comparison between 2 normally distributed continuous variables. Although considered very conservative, we applied a Bonferroni correction for multiple comparisons. We divided 0.05 by the number of disease characteristics tested (13 sets of variables). P value \leq 0.004 was considered statistically significant.

A multivariate stepwise logistic regression analysis was also performed to determine whether the presence of AID was associated with the various phenotypes of SSc. We included in our multivariate model all variables identified with a corrected p value < 0.1 univariately¹⁸, with calculation of OR estimates and 95% confidence intervals (CI) for significant variables (OR and p value were not provided by the software when not significant). In this model, p value < 0.05 was considered statistically significant.

RESULTS

Study population. We included 547 patients with SSc from Italy and 585 from France. The mean age was 57 ± 14 years in the French cohort and 63 ± 14 years in the Italian cohort ($p < 0.0001$). The mean disease duration was 11 ± 9 years in the French cohort and 13 ± 8 years in the Italian cohort ($p < 0.0001$). These measures were significantly higher in the Italian cohort: the frequency of the limited cutaneous subtype (75% vs 67%; $p = 0.004$), ANA (99% vs 86%; $p < 0.0001$), ACA (50% vs 33%; $p < 0.0001$), altered DLCO (DLCO/AV < 75%: 52% vs 32%; $p < 0.0001$), and PAH (13.5% vs 8%; $p = 0.001$). A description of the French and Italian cohorts is provided in Table 1.

Prevalence of associated AID in both cohorts. AID were found in 87/585 (15%) of patients with SSc in the primary French cohort and 152/547 (28%) of patients in the Italian cohort ($p < 0.0001$) (Table 3). SS and thyroiditis were the predominant AID in both cohorts but with higher prevalence in the Italian (17% vs 7.5%, $p < 0.0001$, for SS and 8.5% vs 4%, $p = 0.025$, for thyroiditis). The prevalence of myositis, PBC, RA, and SLE was similar in both cohorts.

Relationship between AID and SSc features. Table 4 gives the results of multiple corrected chi-squared analyses for each AID.

SS (137/1132, 12%) was associated in multiple stepwise logistic regression analysis with the limited cutaneous subtype (OR 2.7, 95% CI 1.4–5.3).

The presence of autoimmune thyroiditis (70/1132, 6%) was associated with a lower frequency of pulmonary fibrosis (OR 0.3, 95% CI 0.1–0.7; Table 4).

Table 1. Characteristics of study participants: French and Italian Caucasian patients with SSc.

Characteristics	SSc Patients from France (n = 585)	SSc Patients from Italy (n = 547)	p	Combined population
Sex (women/men)	498/87	491/56	0.06	989/143
Age (yrs), mean ± SD	57 ± 14	63 ± 14	< 0.0001	60 ± 14
Cutaneous subtype (L/D), n (%)	394 (67)/191 (33)	411 (75)/136 (25)	0.004	805 (71)/327 (29)
Disease duration (yrs), mean ± SD	11 ± 9	13 ± 8	< 0.0001	12 ± 8
History of digital ulcers, n (%)	224 (38)	193 (35)	0.32	417 (37)
Pulmonary arterial hypertension, n (%)	45 (8)	74 (13.5)	0.001	119 (11)
Pulmonary fibrosis on CT scan, n (%)	220 (38)	175 (32)	0.04	395 (35)
Scleroderma renal crisis, n (%)	9 (1)	10 (2)	0.25	19 (2)
Antinuclear antibodies (> 1/160), n (%)	503 (86)	543 (99)	< 0.0001	1046 (92)
Antitopoisomerase I antibodies, n (%)	149 (25)	136 (24)	0.75	285 (25)
Anticentromere antibodies, n (%)	193 (33)	276 (50)	< 0.0001	469 (41)
Anti-RNP antibodies	31 (5)	13 (2)	0.01	44 (4)
Decreased FVC (< 75% of normal value), n (%)	80 (13)	86 (16)	0.18	166 (15)
Decreased DLCO/AV (< 75% normal value), n (%)	189 (32)	284 (52)	< 0.0001	473 (42)
Immunosuppressive drugs, n (%)	141 (24)	131 (24)	0.94	272 (24)

SSc: systemic sclerosis; L/D: limited/diffuse; CT: computed tomography; RNP: ribonucleoprotein; FVC: forced vital capacity; DLCO/AV: carbon monoxide diffusion capacity divided by alveolar volume.

Myositis was associated in multivariate analysis with the use of immunosuppressive drugs (OR 11.5, 95% CI 5.1–25.7). PBC (31/1132, 3%) was associated in multivariate analysis with the limited cutaneous subtype (OR 2.1, 95% CI 1.5–2.8) and the presence of ACA (OR 6.2, 95% CI 2.3–16.5).

The number of patients with RA and SLE was too low to perform accurate chi-squared tests to find disease phenotype associations.

In multiple logistic regression analysis, the coexistence of at least 1 AID (239/1132, 21%) in the whole cohort of SSc was associated independently with the limited cutaneous subtype (OR 3.3, 95% CI 2.1–5.3), the presence of ANA (OR 8.6, 95% CI 2.1–35.9), and a lower prevalence of digital ulcers (OR 0.6, 95% CI 0.4–0.9).

The coexistence of at least 2 AID associated with SSc was associated only with the limited cutaneous subtype ($p = 0.04$).

DISCUSSION

Our main results from these large series of consecutive patients, performed in centers accustomed to the systematic evaluation of patients with SSc, show that about a quarter of European Caucasian patients with SSc have developed 1 or more AID known to be associated with CTD. Moreover, the presence of these AID was associated with a subset of patients with milder disease, defined by the predominance of the limited cutaneous subtype, and a lower frequency of digital ulceration.

Our study shows differences between the French and Italian cohorts. Italian patients were significantly older, their disease duration was significantly longer, and we found a higher percentage of patients with the limited cutaneous

subtype. Positive ACA were detected more frequently in Italian patients, which may explain the higher frequency of the limited cutaneous subtype and PAH, as these antibodies are usually detected in limited pattern in the disease and are positively correlated with development of PAH^{3,6,19}. These data are in accord with a recent study, performed by the EULAR Scleroderma Trials and Research group (EUSTAR), that assessed the geographic variation of disease manifestations in SSc²⁰.

Although they were more frequent in the French population, the frequency of antiribonucleoprotein antibodies was low in both cohorts and was not associated with any SSc characteristics. This raises the question of the role of these antibodies as biomarkers or agents of disease pathogenesis.

We found that the prevalence of associated AID was 15% in France and 28% in Italy. The difference between these 2 cohorts may partly be explained by the higher frequency of AID in older patients (the Italian patients were older than the French ones) and the association, within the multivariate analysis, between coexistence of at least 1 AID with SSc and the limited cutaneous subtype, significantly more prevalent in the Italian cohort.

Our data show that 21% of this large series of patients developed at least 1 specific AID, with higher occurrence of SS (12%) and autoimmune thyroiditis (6%) than in the general European population (1% to 4% for SS, 1% to 2% for autoimmune thyroiditis)^{21,22}. This supports the hypothesis that SSc may be commonly associated with AID. This prevalence is consistent with those of a recent genetic study, which investigated the autoimmune candidate gene and found that the association between an AID with SSc was 22% in a population of 659 European Caucasians with SSc²³. These data are also close to those of a previous

Table 2. Standard international criteria for the diagnosis of autoimmune diseases.

Disease	International Classification Criteria
Sjögren's syndrome	Four of 6 criteria are necessary for diagnosis: 1. Ocular symptoms 2. Oral symptoms 3. Ocular signs — objective evidence of ocular involvement defined as positive result for at least Schirmer's test or rose Bengal score/other ocular dye score 4. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis evaluated by an expert histopathologist 5. Salivary gland involvement: objective evidence defined by a positive result 6. Autoantibodies: presence in the serum of the following autoantibodies [antibodies to Ro (SSA) or La (SSB) antigens, or both]
Autoimmune thyroiditis	Graves-Basedow's disease: criteria 1 + 2 or 1 + 3 or 2 + 3 1. Hyperthyroidism 2. Exophthalmos 3. Positive Tsh-receptor antibodies Hashimoto's thyroiditis: criteria 1 or 2 + 3 1. Hypothyroidism 2. Goiter 3. Positive antithyroid peroxidase antibodies
Primary biliary cirrhosis	Two of 3 criteria are necessary for diagnosis: 1. Clinical fatigue, pruritus, or jaundice 2. Presence of antimitochondrial antibodies, which are specific markers of the disease 3. Histological evidence of nonsuppurative inflammation of the liver
Systemic lupus erythematosus	Four of 11 criteria are necessary for diagnosis: 1. Malar rash 2. Discoid rash 3. Photosensitivity 4. Oral ulcers: includes oral and nasopharyngeal ulcers, observed by physician 5. Nerosive arthritis 6. Serositis 7. Renal disorder (proteinuria > 0.5 g/24h) 8. Neurologic disorder (seizures without other cause or psychosis without other cause) 9. Hematologic disorders: hemolytic anemia or leukopenia (< 4000/mm ³) or lymphopenia (< 1500/mm ³) or thrombocytopenia (< 100,000/mm ³) in the absence of offending drugs 10. Immunologic disorder: anti-dsDNA, anti-Sm, and/or anti-phospholipid 11. Antinuclear antibodies
Rheumatoid arthritis	Four criteria are necessary for diagnosis: 1. Morning stiffness 2. Arthritis of 3 or more joint areas 3. Arthritis of hand joints 4. Symmetric arthritis 5. Rheumatoid nodules 6. Serum rheumatoid factor 7. Radiographic changes
Myositis	Definite polymyositis = all first 4; probable polymyositis = 3 of first 4; possible polymyositis = 2 of 4. Definite dermatomyositis = rash + 3 other; probable dermatomyositis = rash + 2 other; possible dermatomyositis = rash + 1 other: 1. Symmetrical weakness, usually progressive, of the limb-girdle muscles 2. Muscle biopsy evidence of myositis 3. Elevation of serum levels of muscle-associated enzymes 4. Electromyographic triad of myopathy 5. Characteristic rashes of dermatomyositis

study⁶, which reported that approximately one-third of patients affected by SSc developed 1 or more additional AID. That study included additional AID (as celiac disease or vitiligo) and was not restricted to Caucasian patients, as compared to our study, which may account for the difference from our results. All these results emphasize that patients with SSc should be carefully evaluated both at onset

and during followup for the possible coexistence of other autoimmune disorders. However, the reasons why AID occur together remains unknown, and shared pathophysiological mechanisms remain to be identified. In Caucasian patients, these diseases show a frequent association with HLA-B8, -DR3, and/or -DR4 compared with the general population. Natural killer T cell counts are relatively low in

Table 3. Prevalence of SSc-associated autoimmune disease (AID) in French and Italian cohorts.

Disease [n (%)]	SSc Patients from France, n = 585	SSc Patients from Italy, n = 547	p	Combined Population, n = 1132
Sjögren's syndrome	44 (7.5)	93 (17)	< 0.0001	137 (12)
Autoimmune thyroiditis	23 (4)	47 (8.5)	0.025	70 (6)
Myositis	19 (3)	16 (3)	0.86	35 (3)
Primary biliary cirrhosis	14 (2)	17 (3)	0.37	31 (3)
Rheumatoid arthritis	8 (1)	3 (0.5)	0.53	11 (1)
Systemic lupus erythematosus	6 (1)	3 (0.5)	0.53	9 (1)
At least 1 AID associated with SSc	87 (15)	152 (28)	< 0.0001	239 (21)
At least 2 AID associated with SSc	16 (3)	14 (2.5)	0.74	30 (3)
At least 3 AID associated with SSc	2 (0.3)	2 (0.3)	0.59	4 (0.3)

patients with AID and this may also be true for multiple AID²⁴. In animals, it was reported that thymectomy alone produced multiorgan-specific AID, suggesting that some kind of common immunologic pathway exists²⁵.

The presence of at least 1 AID was associated with the limited cutaneous subtype, ANA, and a lower frequency of digital ulceration, defining a subset of patients with milder disease. This suggests that the limited cutaneous subtype of SSc has a distinct pathogenesis with a greater autoimmune background, and may have implications for the research and trials in a disease in which there is no specific treatment²⁶, although this will require further studies.

The association between AID and the limited cutaneous disease subset, with this autoimmune propensity, may be explained by the distinct expression of the diseases in various ethnic groups, depending on genetic and environmental factors that could predispose to autoimmunity in general, and to certain clinical manifestations of each disease in particular²⁷. The clinical course of patients with SSc may be modified by the previous damage produced by the associated AID. This strongly suggests shared autoimmunity, a common genetic background that would drive predominant autoimmunity within the same family or the same patient. This is highlighted by 3 recent studies. The first²³ showed an association between the *PTPN22* 1858T allele and SSc, indicating that *PTPN22*, a shared genetic factor of multiple autoimmune diseases, also contributes to the genetic background of SSc. The second study found an association between *STAT4* tagging polymorphism and AID²⁸, suggesting that *STAT4* is a novel common risk factor for AID. The third study showed that *IRF5* rs2004640 polymorphism, identified as a susceptibility gene of SLE and SS, was associated with SSc²⁹. Thus, some immune gene may be shared by different diseases. This shared autoimmunity, within the analysis of polymorphisms and mutations of genes linked to autoimmunity in several ethnic groups, should offer an excellent tool for understanding the physiopathology of AID.

AID aggregation has already been assessed in families with primary SS³⁰. A recent study examined the aggregation of AID among first-degree relatives of patients with primary

SS. Their results indicate that diseases with immune disturbances (such as autoimmune thyroiditis, SLE, or SSc) cluster within families of patients with primary SS. This familial aggregation of AID suggests that diseases with distinct phenotypes might share a common susceptibility gene.

Our study had some limitations. Disease phenotype associations have to be considered cautiously as the study was cross-sectional. Moreover, this design did not allow us to determine if AID occurred before or after the diagnosis of SSc and the potential effect of this sequence on the disease phenotype. It was not possible to assess in the whole cohort the segregation of specific autoantibodies, i.e., antimitochondrial antibodies, antithyroid peroxidase antibodies, or anti-Ro/SSA antibodies, as this was done in routine care only in patients with the respective suspected AID. We focused only on European Caucasian patients with SSc; further studies are thus needed to confirm these results in other ethnic groups. Patients were from tertiary centers; this may mean that they experienced more active and severe disease than patients followed in routine care centers. However, all centers involved in this project are highly active in the field of SSc clinical research, a fact that markedly increases the quality and accuracy of the data collected. We also chose to concentrate on a restricted panel of AID known to occur with CTD and which were commonly and systematically assessed in all 11 centers. Further studies are now warranted to assess the coexistence of other AID (e.g., diabetes mellitus or vitiligo) with SSc.

Our study shows that 21% of this large series of European Caucasian patients with SSc has developed 1 or more AID known to occur with CTD. The presence of at least 1 of these AID was associated with the presence of ANA, the limited cutaneous subtype, and lower frequency of digital ulceration. This defines a subset of patients with a milder disease, probably associated with weaker fibrotic or vascular propensities. This strongly suggests that genetic background would drive predominant autoimmunity. Therefore the association of AID in SSc has to be considered for investigations in SSc and in particular for genetic, immune, or therapeutic studies.

Table 4. Associations between AID and systemic sclerosis features.

AID	Disease Phenotype Associations in Univariate Analysis	Patients with AID, n (%) vs Patients without AID, n (%)	p*	Multivariate Stepwise Logistic Regression Analysis OR (95% CI)	p**	
Sjögren's syndrome, (n = 137)	Female, n (%)	127/137 (92) vs 862/995 (87)	0.07		NS	
	Age, mean ± SD, yrs	65 ± 15 vs 62 ± 13	0.5		NI	
	Disease duration, yrs	14 ± 10 vs 12 ± 8	0.02		NS	
	Limited cutaneous subtype, n (%)	115/137 (84) vs 690/995 (69)	0.002	2.7 (1.4–5.3)	0.003	
	History of digital ulcers, n (%)	40/137 (29) vs 377/995 (38)	0.06		NS	
	PAH, n (%)	9/137 (7) vs 110/995 (11)	0.04		NS	
	Pulmonary fibrosis on CT scan, n (%)	38/137 (27) vs 357/995 (36)	0.07		NS	
	ANA (> 1/160), n (%)	134/137 (98) vs 912/995 (92)	0.008		NS	
	Anti-topo, n (%)	21/137 (15) vs 254/995 (26)	0.02		NS	
	ACA, n (%)	79/137 (58) vs 390/995 (39)	0.001		NS	
	Decreased forced vital capacity, n (%)	10/137 (7) vs 156/995 (16)	0.001		NS	
	Decreased DLCO/AV, n (%)	64/137 (47) vs 409/995 (41)	0.6		NI	
	Immunosuppressive drug, n (%)	33/137 (24) vs 239/995 (24)	0.9		NI	
	Autoimmune thyroiditis, (n = 70)	Female, n (%)	68/70 (97) vs 921/1062 (87)	0.04		NS
		Age, mean ± SD, yrs	62 ± 13 vs 62 ± 13	0.9		NI
		Disease duration, yrs	11 ± 9 vs 12 ± 9	0.5		NI
Limited cutaneous subtype, n (%)		55/70 (78) vs 750/1062 (71)	0.2		NI	
History of digital ulcers, n (%)		15/70 (22) vs 402/1062 (38)	0.03		NS	
PAH, n (%)		7/70 (10) vs 112/1062 (10)	0.25		NI	
Pulmonary fibrosis on CT scan, n (%)		13/70 (18) vs 382/1062 (36)	0.001	0.3 (0.1–0.7)	0.004	
ANA (> 1/160), n (%)		66/70 (94) vs 980/1062 (92)	0.06		NS	
Anti-topo, n (%)		14/70 (20) vs 271/1062 (25)	0.4		NI	
ACA, n (%)		41/70 (58) vs 428/1062 (40)	0.02		NS	
Decreased forced vital capacity, n (%)		8/70 (11) vs 158/1062 (15)	0.3		NI	
Decreased DLCO/AV, n (%)		27/70 (39) vs 446/1062 (42)	0.3		NI	
Immunosuppressive drug, n (%)		7/70 (10) vs 265/1062 (25)	0.03		NS	
Myositis, (n = 35)		Female, n (%)	31/35 (88) vs 958/1097 (87)	0.9		NI
		Age, mean ± SD, yrs	64 ± 16 vs 62 ± 13	0.8		NI
		Disease duration, yrs	11 ± 7 vs 12 ± 8	0.4		NI
	Limited cutaneous subtype, n (%)	25/35 (71) vs 780/1097 (71)	0.9		NI	
	History of digital ulcers, n (%)	11/35 (31) vs 406/1097 (37)	0.6		NI	
	PAH, n (%)	3/35 (10) vs 116/1097 (11)	0.6		NI	
	Pulmonary fibrosis on CT scan, n (%)	17/35 (49) vs 378/1097 (35)	0.09		NS	
	ANA (> 1/160), n (%)	32/35 (91) vs 1014/1097 (92)	0.8		NI	
	Anti-topo, n (%)	9/35 (26) vs 276/1097 (25)	0.9		NI	
	ACA, n (%)	5/35 (14) vs 464/1097 (42)	0.002		NS	
	Decreased forced vital capacity, n (%)	6/35 (17) vs 160/1097 (14)	0.9		NI	
	Decreased DLCO/AV, n (%)	15/35 (43) vs 458/1097 (42)	0.9		NI	
	Immunosuppressive drug, n (%)	27/35 (77) vs 245/1097 (22)	< 0.0001	11.5 (5.1–25.7)	< 0.0001	
	Primary biliary cirrhosis, (n = 31)	Female, n (%)	28/31 (91) vs 961/1101 (87)	0.7		NI
		Age, mean ± SD, yrs	65 ± 13 vs 62 ± 12	0.7		NI
		Disease duration, yrs	16 ± 10 vs 12 ± 9	0.008		NS
Limited cutaneous subtype, n (%)		30/31 (97) vs 775/1101 (70)	0.002	2.1 (1.5–2.8)	0.02	
History of digital ulcers, n (%)		6/31 (21) vs 411/1101 (37)	0.06		NS	
PAH, n (%)		2/31 (7) vs 117/1101 (11)	0.8		NI	
Pulmonary fibrosis on CT scan, n (%)		5/31 (16) vs 390/1101 (35)	0.04		NS	
ANA (> 1/160), n (%)		28/31 (91) vs 1014/1101 (92)	0.9		NI	
Anti-topo, n (%)		1/31 (3) vs 284/1101 (26)	0.008		NS	
ACA, n (%)		23/31 (74) vs 446/1101 (40)	0.0003	6.2 (2.3–16.5)	0.003	
Decreased forced vital capacity, n (%)		1/31 (3) vs 165/1101 (15)	0.08		NS	
Decreased DLCO/AV, n (%)		12/31 (39) vs 461/1101 (42)	0.2		NI	
Immunosuppressive drug, n (%)		9/31 (29) vs 263/1101 (24)	0.6		NI	
At least 1 AID, (n = 239)		Female, n (%)	220/239 (92) vs 769/893 (86)	0.02		NS
		Age, mean ± SD, yrs	63 ± 15 vs 59 ± 13	0.01		NS
		Disease duration, yrs	13 ± 10 vs 12 ± 10	0.1		NI
	Limited cutaneous subtype, n (%)	194/239 (81) vs 611/893 (68)	< 0.0001	3.3 (2.1–5.3)	< 0.0001	
	History of digital ulcers, n (%)	64/239 (27) vs 353/893 (40)	0.0007	0.6 (0.4–0.9)	0.02	
	PAH, n (%)	19/239 (8) vs 100/893 (11)	0.3		NI	
	Pulmonary fibrosis on CT scan, n (%)	64/239 (27) vs 331/893 (37)	0.006		NS	
	ANA (> 1/160), n (%)	229/239 (96) vs 817/893 (91)	0.002	8.6 (2.1–35.9)	0.004	
	Anti-topo, n (%)	43/239 (18) vs 242/893 (27)	0.003		NS	
	ACA, n (%)	117/239 (49) vs 372/893 (41)	0.002		NS	
	Decreased forced vital capacity, n (%)	26/239 (11) vs 140/893 (16)	0.006		NS	
	Decreased DLCO/AV, n (%)	105/239 (44) vs 367/893 (41)	0.09		NS	
	Immunosuppressive drug, n (%)	26/239 (30) vs 246/893 (27)	0.07		NS	

AID: autoimmune diseases; PAH: pulmonary arterial hypertension; ANA: antinuclear antibodies; Anti-topo: antitopoisomerase I antibodies; ACA: anticentromere antibodies; CT: computed tomography; DLCO/AV: carbon monoxide diffusion capacity divided by alveolar volume; NS: not significant. NI: not included. * Significant if p < 0.004. ** Significant if p < 0.05.

REFERENCES

1. Allanore Y, Avouac J, Wipff J, Kahan A. New therapeutic strategies in the management of systemic sclerosis. *Expert Opin Pharmacother* 2007;8:607-15.
2. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. *Curr Opin Rheumatol* 2003;15:778-84.
3. Steen VD. Autoantibodies in systemic sclerosis. *Semin Arthritis Rheum* 2005;35:35-42.
4. Senecal JL, Henault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). *J Rheumatol* 2005;32:1643-9.
5. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. *N Engl J Med* 2006;354:2667-76.
6. Caramaschi P, Biasi D, Volpe A, Carletto A, Cechetto M, Bambara LM, et al. Coexistence of systemic sclerosis with other autoimmune diseases. *Rheumatol Int* 2007;27:407-10.
7. Avouac J, Sordet C, Depinay C, Ardizzone M, Vacher-Lavenu MC, Sibilia J, et al. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. *Arthritis Rheum* 2006;54:2243-9.
8. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J Rheumatol* 1988;15:202-5.
9. Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. Conclusion and identification of the core set of variables to be used in clinical investigations. *Clin Exp Rheumatol* 2003;21(3 Suppl 29):S47-8.
10. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis* 2003;62:1088-93.
11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. *Arthritis Rheum* 1997;40:1725.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
14. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. *N Engl J Med* 2003;348:2646-55.
15. Leuschner U. Primary biliary cirrhosis — presentation and diagnosis. *Clin Liver Dis* 2003;7:741-58.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975;292:344-7.
17. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). *N Engl J Med* 1975;292:403-7.
18. Allanore Y, Meune C, Vonk MC, Airò P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. *Ann Rheum Dis* 2010;69:218-21.
19. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. *J Rheumatol* 2005;32:1488-94.
20. Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. *Ann Rheum Dis* 2009;68:856-62.
21. Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjögren's syndrome: where are we now? *Clin Exp Rheumatol* 2007;25:1-4.
22. Orgiazzi J. The spectrum of autoimmune thyroid diseases (AITD). *Ann Med Interne* 1999;150:294-300.
23. Dieude P, Guedj M, Wipff J, Avouac J, Hachulla J, Diot E, et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. *Arthritis Rheum* 2008;58:2183-8.
24. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. *J Immunol* 2001;167:3129-38.
25. Bonomo A, Kehn PJ, Payer E, Rizzo L, Cheever AW, Shevach EM. Pathogenesis of post-thymectomy autoimmunity. Role of syngeneic MLR-reactive T cells. *J Immunol* 1995;154:6602-11.
26. Allanore Y, Kahan A. Treatment of systemic sclerosis. *Joint Bone Spine* 2006;73:363-8.
27. Rodriguez-Reyna TS, Alarcon-Segovia D. The different faces of shared autoimmunity. *Autoimmun Rev* 2006;5:86-8.
28. Martinez A, Varade J, Marquez A, Cenit MC, Espino L, Perdigones N, et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. *Arthritis Rheum* 2008;58:2598-602.
29. Dieude P, Guedj M, Wipff J, Avouac J, Fajardy I, Diot E, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. *Arthritis Rheum* 2009;60:225-33.
30. Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sjögren's syndrome. *J Rheumatol* 2006;33:2227-34.